Skip to Main Content
Submit your project or idea
Co-create with community
20 votes
Refine your idea
Submit your final proposal
Jury review (pending)
Thanks for your vote
This voting milestone has now ended, and the idea has progressed to a private milestone
Return to idea list
Thanks for approving the idea
This milestone has now ended, and the idea has progressed to a private milestone
Return to idea list

Tissu.ee

by Tamas Czegledi | Jul 7, 2020 | in Digital change-maker challenge | Regulatory and market environment

Human tissue exchange on blockchain. Smart contract driven  platform for a fault tolerant tracking of tissue donors and donatums.

Tissu.ee is a market place for human tissues and products for healthcare professionals where transactions are registered in a distributed ledger.

We aim to provide an integrated searching, comparing and purchasing system for tissue establishments to exchange raw materials, transfer technology and commercialize their products among themselves and also for implant centers to make a wider range of products available.

Our vision is a tokenized tissue ecosystem covering everything from donors to recipients including means of exchange.

We start with a virtual tissue marketplace for medical practitioners and an application for take over administrative burden from the doctors by a QR code system.

As a next step we add a blockchain transaction register to ensure the long-term traceability and storing of vigilance data.

After that we tokenize transactions for easier handling data.

Our integrity token will be awarded by a means of exchange function for tissue bankers and B2B market.

The final steps are to bring these tokens to the wallets of patients.

Define three specific objectives that you would like to achieve with your proposal.

  • Better human tissue supply for the European patients - increase both in accessible volume and quality.
  • Higher level of trust thanks to the immutable tracking and fault-tolerant data storing related to the interstate (and internal) transactions and comparability of technologies and products by channeling credible feedback from practitioners and and manipulation free
  • Access to data - currently there are no available clinical, academic and business data, neither for the actors of market nor for the regulators.

What problems (particularly in value chain competitiveness and global disruption) are your community’s stakeholders facing due to the Covid-19 pandemic?

We focus on the challenges the EU resident patients (human tissue implant recipients) have to face.

B2C customer side: surgeons are facing a shrunken supply of processed tissue products.

B2B customers - tissue banks and hospitals: set back in access to raw material (tissues) because of the lack of surgeries and the serology  related challenges.

What minimum viable solution(s) are you proposing to address the challenge(s) in your community?


We are standardizing raw material collecting processes by using the accumulated knowledge and protocols of all our existing partners and market players, so democratizing supply and bring new players in the supply chain.

Share your story (your narrative)

Having worked for multiple years in the human tissue area, we realized that unlike organs, the supply is uncertain in volume and also in qulaity. The reason behind - as we identified - is the lack of (1) data, (2) connections and networks, (3) efficiency and (4) incentives.

We create an ecosystem for a more efficient tissue donation and a better coverage of best practice and cutting edge technologies by serving the demand from hospitals through tissue banks to implant centers and with tracking transactions across borders from the donors to the recipients. Besides bringing #blockchain in #MedTech we are catalyzing scientific co-operations and creating business opportunities while offering domain specific consulting and professional education.

  • Founded in 2018
  • Raised HUF 27 Million 2 successful seed investment rounds with small investors on a valuation of HUF 200 Million.
  • Legitimation
    • Meddictive Multi-Tissue Bank got its full tissue establishment license in 2019
    • Keynote / presentation 2x on EATCB conferences in Lille and in Leiden and participation on Osteology Symposium in Barcelona. All of them financed by Input Program.
  • Education
    • University Course: Tissue therapies, tissue banking technologies and banking management at Semmelweis University Faculty of Health Sciences
      • 2018/19 academic year: completed
      • 2019/20 academis year: interrupted by COVID-19, online education material under development
  • Contracts
    • Plovdiv University Dental Faculty
      • cooperation on a functional Bulgarian tissue banking facility at the university campus to foster networking in the Balkans
    • Pécs University Dental Faculty
      • cooperation on representation of Pécs University’s tissue banking activities (connective and cornea) in the European tissue sector
    • Petz Aladár County Teaching Hospital
      • cooperation on connective tissue harvesting, manufacturing, processing, packaging, labelling, translation services, logistics, marketing and delivery
      • cooperation on xenograft (pork skin grafts for burnt patients) export
  • Commercial activites
    • Petz Aladár County Teaching Hospital – Tissuemed - Meddictive
    • Tutogen Medical GmbH
      • providing raw material (whole supply chain according tot he German standards – strictest protocoll in Europe)
        • whole femur
        • fascia lata
        • parasternal cartilage
    • ECATB (Austrian tissue bank)
      • providing marketing and commercialization services for Austrian products in CEE and the Balkans
  • platform will start…
  • first raw material coop with Germany…

Please provide any additional relevant information that you would like to share.

SoHOs (Substances of Human Origin: blood, organs, stem cells, etc.) were always harvested and provided inside the boundaries of a country. Because of strict national regulations, sophisticated technology and limited demand, cross-border or international cooperation was limited and the globalization of the SoHO sector only became a reality in recent decades.

We promise to increase the pie by democratizing the market offering access to the market for new partners (hospitals and univeristies not active in this field).

We make medical tissues and related technologies and tools widely available in large numbers, in terms of the legal framework and the economic conditions necessary for our operation. The whole system is freezed and paralized inside individual countries and all stakeholders became familiar with how to maximize operation efficiency under suboptimal circumstances building a high entry barrier to any change management initiatives. Our claim is providing a more transparent and profitable environment for the most important stakeholders, and scientific data, and business data and economies of scale resulting from cooperation by networking different regulation systems.

In practical terms we create two platforms: one for the raw materials for transacting between hospitals and manufacturing entities and another one for the processed products transacting between manufacturers and customers eg. (mainly private) implantologists and (mainly private) surgeons.

Further stages of development

  • Our mobile app will help track the movement of tissues and lightening the administrative burden of surgeons.
  • The distributed ledger will help register and store tissue transactions.
  • At a later stage we can build on these developments to create an ecosystem including payment between patients and surgeons by creating a native token to act as a mean of exchange and providing wallets for patients.

Your Final Proposal for challenge

yes

Idea image
edited on Aug 31, 2020 by Tamas Czegledi
Public (19)
You will need to login to post a comment
Nivashini Rave Rattey Jul 8, 2020

Hi, thanks for sharing the overview of your idea! It is interesting!

Here are some quick suggestions to help you refine your idea:

1. You may want to give more clarity in your very first answer by addressing the demographics of your target audience and why this specific group of people are targeted at. What exactly their problem is and how your solution will solve it via its unique feature.

2. When discussing the problem in question 3, you may want to provide more details. Address the problems your target audience faced prior to COVID-19, in the present due to COVID-19 and in the future - if it is still not addressed. Also, include information on existing solutions to this problem and why they are not working.

3. Your answer to question 4 (solution), should include details about the opportunities that you tapped on to, the unique feature that will fulfill your brand promise to benefit the specific group target audience.

4. Please refer to our storytelling walk-through video to further enhance your existing story.

Users tagged:

Avatar for Tamas Czegledi Tamas Czegledi

Tamas Czegledi Jul 9, 2020

Thanks for your comment and questions!
1. demography: European Union. However, the target audience is the practitioners working with human tissues (surgeons, universities, tissue bankers), the beneficiaries are the patients, so the people of Europe. The problems are: there is no data available on the usage (way, volume and technology) of tissues because of many reasons, there is no efficient connections between the tissue entities and no incentivization for more and better tissue collection. Our system solves these as a main function.
2. there is no way to elaborate this further here without being too technical, but to oversimplify it: the new virus is a new challenge for an already underperforming segment. The challenge is faced in both sides (demand and supply), as the healthcare is becoming even more cautious with invasive treatments and need to filter for a new threat.
3. you mean technical or platform wise?

Israel Abazie Jul 11, 2020

While your tissue marketplace app incorporating distributed ledger technology is amazing, I think you should highlight more how you will determine the quality of the tissues procured for transactions considering the voidness Covid19 is leaving in its wake. And ultimately, what will be the incentives for the donors. Your on to something great, please don't lose sight of that

Tamas Czegledi Jul 11, 2020

The quality of the tissue is not on us. This is the discretion and responsibility of the organization managing the donation and the "producer" or the processing entity. Certainly, there is a strict distinction between "raw material" and processed/finished products, but in any case, they are standalone and registered healthcare institutions, meaning they are allowed to treat tissues according their own legislation and through this, in the EU. What we can do is:
(1) we can verify the way of the tissue and the way they are treated and all the activities performed though. In this case, the question is still there: validation. It requires human interaction at this stage, and as such is prone to mistreatment however with DLT technology all this is traceable and it is accountable.
(2) we can collect empirical data of possible complications and feedback and let the professionals draw conclusions based on that. However strange and scary it is, there is no such a solution in place at this point. (2/a) Meaning, we have no data typical complication ratio in general, because two factor is missing from the equation: the total volume of implantation in EU and in each member state and the number of complications.
(2/b) we have obviously no data on the combination of indications and technologies and products and sources.
(3) there is also missing an umbrella solution for synthesizing different data storing and processing solutions in place. They are valid exclusively for tracking the movement of tissues between institutions and through borders from the donor to the recipient over time. With DLT technology this can easily be solved through a hash pointer to the handler of the actual data without actually handling or keeping the sensible info.

As for the last part of your question: it is strictly forbidden to incentivize the donors. This is a ideological and as such legal question. the legislator is thinking of the organs. Human beings can not be motivated to "sell body parts" and this is the main ideology applied here as well, however tissues are typically surgical waste to be treated as biohazard. If we can keep them within the healthcare system, they are as valuable as organs for treating patients. What we can do is incentivizing the health workers by administrative methods to bring the tissue in the tissue bank instead of the waste bin.

Steve Liddle Jul 16, 2020

As vital now as early organ donor facility - well done. Anything that can guarantee that and donor confidentiality would enhance the critical speed factor. All the best - you have my vote.

Nivashini Rave Rattey Jul 17, 2020

The idea has been progressed to the next milestone.

Sunday Bawa Jul 20, 2020

Hi, a referral reward system should be put in place, is this a website, app or USSD or all of the mentioned? Nice work!

Tamas Czegledi Jul 22, 2020

This is basically website (web platform) with an app as a support for helping the administration for medical practitioners (mainly surgeons). That is an important function as growing (and never really fulfilled) administration is a huge painpoint for them. Considering the long-term vision it will include also a wallet.

Sunday Bawa Jul 22, 2020

Please include this information under the last question: "please provide any additional relevant information that you would like to share"

Sunday Bawa Jul 22, 2020

You could put it as in scaling of business for platform...

Ronnex Wataya Jul 21, 2020

way to go

Victoria Masso Jul 21, 2020

Status label added: Mentor feedback received

Nivashini Rave Rattey Jul 22, 2020

Status label added: Community feedback received

Enyika Iheanyichukwu Jul 23, 2020

Your idea sound good and will be helpful if well implemented. The idea of B2B and B2C will help reduce costing too.

Yvon KOUDAM Jul 23, 2020

very nice initiative especially from the blockchain.
My question is in the face of the growing rise of health applications, how does your business model free you from the competition?

Uche Udekwe Jul 24, 2020

really nice

Tamas Czegledi Jul 26, 2020

The question is good, and the answer is not simple. We have a complex ecosystem as a vision, and however a big chunk of the realization is postponed to the future (as we claim it on a transparent manner) and start with a focused activity, we have been working on the parallel processes and some of them are already creating revenue. To sum up the reasons:
- the number of people with a deep understanding of digital solutions and blockchain and tissues are very limited
- the tissue area requests a sophisticated communication and cooperation with public administration, universities and businesses
- an understanding of public servants and business mindset is necessary and dealing Western and Eastern European actors
- existing professional and business network and experience
- tested logistical and business processes to virtualize and move them on chain
I guess, these are the main reasons of the lack of a strong competition so far.

Yvon KOUDAM Jul 27, 2020

Okay. very nice. congratulations

Uche Udekwe Jul 24, 2020

wooow..a market place for human tissue.. this is really out of the box. very different.. great job

Achia Khaleda Jul 25, 2020

Where are you implement the blockchain technology? Is it a web platform? The idea is great.

Tamas Czegledi Jul 26, 2020

Yes, a web platform. :)
Thanks for the feedback.

Achia Khaleda Jul 27, 2020

you are most welcome. Wish you all the best for your project :)

Davidson Akujiofor Aug 16, 2020

How do you ensure genuine source of the product?

Tamas Czegledi Aug 31, 2020

I do not ensure anything but the trustworthiness of the data. If one raw material is not good enough or problematic anyways, we can trace it back to the source. All the participants are registered tissue entities, it is their requirement and responsibility (toward their legislator) to comply. But we can detect systemic risks and unique mistreatments, just like drawing conclusions on the compatibility of raw materials, processes, technologies, and in some cases also operation indications.

DJ Koeman Aug 27, 2020

Hi there, interesting concept, but where is the necessity of blockchain or DLT in this? What current problem is DLT addressing in this case?
In the meantime, you may want to have a look at our idea and vote for it if yo like it: https://cocreate.itu.int/post/3496670

Tamas Czegledi Aug 31, 2020

In short-term e register TXs in DLT, mid-term we bring in secure ID management for a trustworthy rating system, so medical practitioners can give objective feedback - as compared to getting info from salesmen - and finally, we will tokenize tissue transactions and offering an internal mean of exchange for the participants. Besides, we create real-time data on tissue transactions on different access levels and purposes.

Muyunda Kaonga Aug 27, 2020

Hello Tamas, this is really a brilliant idea. You're doing amazing things awesome submission. How are people currently solving this and what is your value proposition? What risks are involved and how will you address them? All the best in your project

Tamas Czegledi Aug 31, 2020

We are certainly facing several risks, but we trust in our competence and experience, and we are sure, we can tackle all the challenges in front of us.:
1. Eastern European entities are typically not good at complying with Western parties. We are working on to standardize different expectations and translate it to check list and guidelines and we offer our expertise as a source of education in the same time.
2. Physicians (doctors) are far from being geeks. We move ahead slowly, step-by-step. We detect the largest pains of each participant and offer a solution to it right away. We focus on the most affected players and use them as a point of reference.
3. Legislations are different from member state to member state. We study the different legislations and contact the relevant bodies and comply with them strictly. We will push the system to the limit, but for sure, strictly stay within each legislators' range of acceptance.

Nivashini Rave Rattey Sep 3, 2020

Status label added: Submission completed

Nivashini Rave Rattey Sep 8, 2020

Status labels added: Idea under jury review, Idea not yet mature

Nivashini Rave Rattey Sep 8, 2020

Status label removed: Idea not yet mature

Nivashini Rave Rattey Sep 8, 2020

The idea has been progressed to the next milestone.